# Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

> **NCT05563844** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chengdu Zenitar Biomedical Technology Co., Ltd** · enrollment: 74 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma，DLBCL

## Interventions

- **DRUG:** PM 8.4 mg/m^2
- **DRUG:** PM 11.2 mg/m^2

## Key facts

- **NCT ID:** NCT05563844
- **Lead sponsor:** Chengdu Zenitar Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-08
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-01
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05563844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05563844, "Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05563844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*